Listed by the USPTO as DHARITHREESAN, NIDHI
Tech Center 1600 • Art Units: 1672 1686
This examiner grants 40% of resolved cases
DHARITHREESAN, NIDHI is assigned to Tech Center 1600 and Art Unit 1672. The record includes 55 resolved cases, a 40.0% allowance rate, and a median of 1790 days to allowance. The 33.1% interview lift is meaningful relative to the allowance rate, making interviews a potentially important tool for addressing prosecution obstacles.
The listed companies are Grail LLC, NEC Corporation, and X Development LLC. The listed firms are BakerHostetler, DENTONS BINGHAM GREENEBAUM LLP, and DORITY & MANNING, P.A. The low allowance rate and lengthy median timeline support early strategic planning, including claim review, interview preparation, and realistic client expectations about prosecution duration.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18030824 | INFORMATION PROCESSING APPARATUS, INFORMATION PROCESSING METHOD, AND STORAGE MEDIUM | Non-Final OA | NEC Corporation |
| 19435464 | PLATFORMS, SYSTEMS, AND METHODS FOR DATA NORMALIZATION FOR MACHINE LEARNING | Non-Final OA | X Development LLC |
| 18167794 | TREATMENT PARAMETER ESTIMATION | Non-Final OA | Align Technology, Inc. |
| 18021573 | SYSTEMS AND METHODS FOR ENFORCING CONTACT TRACING | Non-Final OA | SIGNIFY HOLDING B.V. |
| 17490615 | ANTI-COUNTERFEIT TAGS USING HIGH-COMPLEXITY POLYNUCLEOTIDES | Final Rejection | MICROSOFT TECHNOLOGY LICENSING, LLC |
| 17491276 | TECHNIQUES FOR ACCELERATING SMITH-WATERMAN SEQUENCE ALIGNMENTS | Non-Final OA | NVIDIA CORPORATION |
| 17738199 | COMPUTERIZED DECISION SUPPORT TOOL FOR PREVENTING FALLS IN POST-ACUTE CARE PATIENTS | Final Rejection | CERNER INNOVATION, INC. |
| 18058487 | SEQUENCE ALIGNMENT SYSTEMS AND METHODS TO IDENTIFY SHORT MOTIFS IN HIGH-ERROR SINGLE-MOLECULE READS | Non-Final OA | Roche Sequencing Solutions, Inc. |
| 18040928 | ANALYSIS WORK SUPPORT DEVICE AND ANALYSIS WORK SUPPORT SOFTWARE | Final Rejection | SHIMADZU CORPORATION |
| 17259128 | METHODS AND SYSTEMS FOR DETECTING AND QUANTIFYING NUCLEIC ACIDS | Final Rejection | GEN-PROBE INCORPORATED |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy40.0% of resolved applications examined by Nidhi Dharithreesan were allowed (55 resolved cases), compared with 38.3% across Art Unit 1672 over the last five years.
This examiner's interview lift is +33.1 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Nidhi Dharithreesan took 1,790 days on average from filing to allowance.
Nidhi Dharithreesan examines applications in Art Unit 1672 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
